Mark Wainberg

Q: What Schools Are Affiliated With Mark Wainberg

Mark Wainberg is affiliated with the following schools: Nanchang University, University of Amsterdam, Université de Montréal, McGill University, University of British Columbia, University of Manitoba, Columbia University

Mark Wainberg's AcademicInfluence.com Rankings

Mark Wainberg

Philosophy

#3949

World Rank

#6290

Historical Rank

Logic

#1655

World Rank

#2460

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Mark Wainberg's Degrees

PhD Biochemistry Columbia University
Bachelors Chemistry McGill University

Why Is Mark Wainberg Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Mark Arnold Wainberg, was a Canadian HIV/AIDS researcher and HIV/AIDS activist. He was the Director of the McGill University AIDS Centre at the Montreal Jewish General Hospital and Professor of Medicine and of Microbiology at McGill University. His laboratory primarily studies HIV reverse transcriptase, the molecular basis for drug resistance, and gene therapy. He received a B.Sc. from McGill University in 1966, a Ph.D. from Columbia University in 1972, and did his post-doctoral research at Hadassah Medical School of the Hebrew University.

(See a Problem?)

Mark Wainberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. (2015) (1182)
A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients: the INCAS trial (1998) (746)
High rates of forward transmission events after acute/early HIV-1 infection. (2007) (676)
Public health implications of antiretroviral therapy and HIV drug resistance. (1998) (520)
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. (2017) (316)
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase (1993) (314)
Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase (1996) (309)
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors (2003) (308)
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. (1998) (286)
In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA (1998) (271)
Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy (1998) (264)
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. (2003) (251)
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture (2006) (240)
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine (1993) (238)
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine (1992) (232)
Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection (2002) (226)
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (2011) (224)
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog (1991) (218)
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine (1994) (216)
Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use (2000) (213)
CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. (2016) (203)
Methylation of Tat by PRMT6 Regulates Human Immunodeficiency Virus Type 1 Gene Expression (2005) (195)
Development of antiretroviral drug resistance. (2011) (191)
Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles (1994) (190)
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA (2015) (188)
The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis (2000) (179)
Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy (1989) (174)
Description and application of a system for locomotor rehabilitation (1987) (169)
RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a Protease-Mediated Sequestration of RIG-I (2010) (167)
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization (1997) (164)
The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus (1992) (164)
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. (1995) (154)
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine (1992) (151)
The role of unintegrated DNA in HIV infection (2011) (146)
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. (1995) (143)
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection (2004) (139)
Whither or Wither Microbicides? (2008) (139)
Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site (1996) (137)
Animal rights. (1992) (135)
Arginine Methylation of the Human Immunodeficiency Virus Type 1 Tat Protein by PRMT6 Negatively Affects Tat Interactions with both Cyclin T1 and the Tat Transactivation Region (2007) (134)
Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT (2002) (132)
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure (2013) (129)
HIV-1 subtype distribution and the problem of drug resistance (2004) (128)
Transmission networks of drug resistance acquired in primary/early stage HIV infection (2008) (128)
HIV drug resistance against strand transfer integrase inhibitors (2017) (128)
The Transmembrane Domain of BST-2 Determines Its Sensitivity to Down-Modulation by Human Immunodeficiency Virus Type 1 Vpu (2009) (127)
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. (1999) (126)
High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens (2006) (125)
Development of HIV‐1 resistance to (−)2′‐deoxy‐3′‐thiacytidine in patients with AIDS or advanced AIDS‐related complex (1995) (124)
Role of the Mononuclear Phagocyte System in the Development of Acquired Immunodeficiency Syndrome (AIDS) (1988) (121)
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication (1994) (120)
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription (1996) (120)
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition (2012) (120)
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? (2004) (119)
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. (2011) (117)
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. (1994) (116)
Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. (1992) (114)
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency (2013) (112)
Characterization of a Putative α-Helix across the Capsid-SP1 Boundary That Is Critical for the Multimerization of Human Immunodeficiency Virus Type 1 Gag (2002) (111)
Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations (2011) (104)
Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. (1991) (100)
Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase (1997) (100)
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. (1994) (98)
Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1 (2008) (95)
Incorporation of excess wild-type and mutant tRNA(3Lys) into human immunodeficiency virus type 1 (1994) (94)
Natural Killer Cell Function in Patients With Acquired Immunodeficiency Syndrome and Related Diseases (1989) (94)
Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. (2008) (94)
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. (1997) (94)
Impact of Human Immunodeficiency Virus Type 1 RNA Dimerization on Viral Infectivity and of Stem-Loop B on RNA Dimerization and Reverse Transcription and Dissociation of Dimerization from Packaging (2000) (92)
Tetherin restricts direct cell-to-cell infection of HIV-1 (2010) (91)
Cell surface down‐modulation of CD4 after infection by HIV‐1 (1994) (88)
Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008) (2009) (88)
Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor (2010) (87)
Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors (2012) (85)
Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. (1990) (85)
Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2 (2009) (84)
Detection of human immunodeficiency virus type 1 (HIV-1) in genital ulcer exudate of HIV-1-infected men by culture and gene amplification. (1990) (82)
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine (1995) (82)
The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity (1997) (82)
The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. (1988) (82)
Effects of Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 in Cell-free Recombinant Reverse Transcriptase Assays (*) (1995) (80)
The Role of Pr55gag in the Annealing of tRNA3Lys to Human Immunodeficiency Virus Type 1 Genomic RNA (1999) (80)
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. (2013) (80)
Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. (1974) (79)
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance (2002) (78)
Promote HIV Chemoprophylaxis Research, Don't Prevent It (2005) (77)
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells (1990) (77)
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness (2014) (77)
A Structurally Disordered Region at the C Terminus of Capsid Plays Essential Roles in Multimerization and Membrane Binding of the Gag Protein of Human Immunodeficiency Virus Type 1 (2003) (76)
Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1 (1991) (75)
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing (2015) (75)
Clinical correlates of in vitro HIV‐1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial (1993) (74)
Subtype diversity associated with the development of HIV‐1 resistance to integrase inhibitors (2011) (74)
Novel therapeutic strategies targeting HIV integrase (2012) (74)
Inducible Expression of IκBα Repressor Mutants Interferes with NF-κB Activity and HIV-1 Replication in Jurkat T Cells* (1998) (73)
25 years of HIV-1 research – progress and perspectives (2008) (72)
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics (2008) (71)
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. (1995) (71)
Association of p56lck with the cytoplasmic domain of CD4 modulates HIV‐1 expression. (1994) (71)
Primer tRNA3Lys on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1 (1997) (70)
The impact of the M184V substitution on drug resistance and viral fitness. (2004) (69)
Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases. (1996) (69)
Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. (1996) (69)
Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. (1997) (68)
HIV Resistance to Nevirapine and Other Non‐Nucleoside Reverse Transcriptase Inhibitors (2003) (68)
Sequences Downstream of the 5′ Splice Donor Site Are Required for both Packaging and Dimerization of Human Immunodeficiency Virus Type 1 RNA (2003) (68)
Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1. (2000) (68)
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. (2009) (68)
Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. (1993) (67)
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. (2002) (67)
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine (2001) (67)
PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA (2006) (67)
Evolution of HIV integrase resistance mutations (2012) (67)
Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 Infection (2004) (67)
Mechanism of Action and In Vitro Activity of 1′,3′-Dioxolanylpurine Nucleoside Analogues against Sensitive and Drug-Resistant Human Immunodeficiency Virus Type 1 Variants (1999) (66)
Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors (2006) (66)
The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs (2012) (66)
Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes (2010) (65)
Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1 (1996) (65)
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. (2012) (64)
Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. (1995) (64)
Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells (1990) (63)
Role of RNA in Facilitating Gag/Gag-Pol Interaction (2002) (63)
Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis (2015) (63)
Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine (2013) (62)
Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors (2017) (62)
Pathogenesis and therapy of HIV-1 infection of the central nervous system. (1992) (62)
Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase (2003) (61)
Anti-Human Immunodeficiency Virus Type 1 Activity, Intracellular Metabolism, and Pharmacokinetic Evaluation of 2′-Deoxy-3′-Oxa-4′-Thiocytidine (1999) (61)
Biochemical Mechanism of HIV-1 Resistance to Rilpivirine* (2012) (61)
Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1 (1997) (60)
Virulence and Reduced Fitness of Simian Immunodeficiency Virus with the M184V Mutation in Reverse Transcriptase (2002) (60)
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study (2017) (60)
Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. (1996) (60)
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1. (1997) (60)
Eurifoloids A-R, structurally diverse diterpenoids from Euphorbia neriifolia. (2014) (60)
Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase (2013) (60)
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study (2017) (60)
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine (1993) (60)
Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. (2000) (59)
Cellular immunity against Rous sarcomas of chickens. Preferential reactivity against autochthonous target cells as determined by lymphocyte adherence and cytotoxicity tests in vitro. (1974) (59)
The role of Tat in HIV-1 replication: an activator and/or a suppressor? (2002) (59)
Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase (2014) (58)
Might the M184V substitution in HIV-1 RT confer clinical benefit? (2002) (58)
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. (2017) (58)
Variant effects of non-native kissing-loop hairpin palindromes on HIV replication and HIV RNA dimerization: role of stem-loop B in HIV replication and HIV RNA dimerization. (1999) (58)
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro. (1995) (58)
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors (2014) (58)
Mutation of the SP1 Sequence Impairs both Multimerization and Membrane-Binding Activities of Human Immunodeficiency Virus Type 1 Gag (2005) (58)
The development of novel HIV integrase inhibitors and the problem of drug resistance. (2012) (57)
HIV transmission and primary drug resistance. (2006) (56)
Role of Antibody‐Dependent Cellular Cytotoxicity and Lymphokine‐Activated Killer Cells in AIDS and Related Diseases (1991) (56)
Effects of modifying the tRNA(3Lys) anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription (1996) (56)
The K65R Mutation Confers Increased DNA Polymerase Processivity to HIV-1 Reverse Transcriptase* (1996) (56)
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. (2016) (55)
Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of Dengue virus replication# (2017) (55)
Diminished RNA Primer Usage Associated with the L74V and M184V Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Provides a Possible Mechanism for Diminished Viral Replication Capacity (2003) (55)
The Role of Nucleocapsid and U5 Stem/A-Rich Loop Sequences in tRNA3Lys Genomic Placement and Initiation of Reverse Transcription in Human Immunodeficiency Virus Type 1 (1998) (55)
Roles of the Human Immunodeficiency Virus Type 1 Nucleocapsid Protein in Annealing and Initiation versus Elongation in Reverse Transcription of Viral Negative-Strand Strong-Stop DNA (1998) (55)
HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays (2010) (54)
Temporal Coordination between Initiation of HIV (+)-Strand DNA Synthesis and Primer Removal* (1999) (54)
Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain (2017) (53)
Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity (2013) (53)
Stage-Dependent Inhibition of HIV-1 Replication by Antiretroviral Drugs in Cell Culture (2009) (53)
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. (2004) (52)
Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. (2007) (52)
Compensatory Point Mutations in the Human Immunodeficiency Virus Type 1 Gag Region That Are Distal from Deletion Mutations in the Dimerization Initiation Site Can Restore Viral Replication (1998) (52)
Arginine methylation of the HIV-1 nucleocapsid protein results in its diminished function (2007) (52)
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence (2015) (52)
Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance (2009) (52)
Pre-Exposure Chemoprophylaxis (PREP) as an HIV Prevention Strategy (2003) (51)
CRISPR/Cas9: a double-edged sword when used to combat HIV infection (2016) (51)
Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs (1991) (51)
Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells (1990) (51)
HIV-1 drug resistance: can we overcome? (2002) (51)
Productive Entry of HIV-1 during Cell-to-Cell Transmission via Dynamin-Dependent Endocytosis (2013) (51)
The Viral Protein Tat Can Inhibit the Establishment of HIV-1 Latency (2012) (50)
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? (2003) (50)
Chlamydia trachomatis infections in infants. (1989) (50)
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations (2007) (50)
Impaired Rescue of Chain-Terminated DNA Synthesis Associated with the L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase (2005) (50)
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. (1999) (49)
Cyclosporine-induced deterioration in patients with AIDS. (1989) (49)
The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses (2002) (49)
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes (2009) (49)
Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication (1996) (49)
The Thiocarboxanilide Nonnucleoside Inhibitor UC781 Restores Antiviral Activity of 3′-Azido-3′-Deoxythymidine (AZT) against AZT-Resistant Human Immunodeficiency Virus Type 1 (1999) (49)
In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine (2011) (49)
The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients (2003) (48)
Antiretroviral therapy : optimal sequencing of therapy to avoid resistance. (2008) (47)
Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. (2003) (47)
A Template-Dependent Dislocation Mechanism Potentiates K65R Reverse Transcriptase Mutation Development in Subtype C Variants of HIV-1 (2011) (47)
The Tat Protein of Human Immunodeficiency Virus Type 1 (HIV-1) Can Promote Placement of tRNA Primer onto Viral RNA and Suppress Later DNA Polymerization in HIV-1 Reverse Transcription (2002) (47)
Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs (2010) (47)
Nature, time course and dose dependence of zidovudine‐related side effects: results from the Multicenter Canadian Azidothymidine Trial (1989) (47)
Structural and functional properties of the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid protein: comparison with the heat-annealed complex. (2002) (47)
Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? (2006) (46)
Regulation of Human Immunodeficiency Virus Type 1 Gene Expression by Clade-Specific Tat Proteins (2005) (46)
Induction of monocytic differentiation and NF-kappa B-like activities by human immunodeficiency virus 1 infection of myelomonoblastic cells (1992) (46)
Roles of Pr55gag and NCp7 in tRNA3Lys Genomic Placement and the Initiation Step of Reverse Transcription in Human Immunodeficiency Virus Type 1 (2000) (45)
Time to act: global apathy towards HIV/AIDS is a crime against humanity (2002) (45)
Alcoholism and rapid progression to AIDS after seroconversion. (1994) (45)
Has the time come to abandon efavirenz for first-line antiretroviral therapy? (2014) (45)
Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline (2013) (45)
Nucleotide and Amino Acid Polymorphisms at Drug Resistance Sites in Non-B-Subtype Variants of Human Immunodeficiency Virus Type 1 (2004) (45)
Resistance Issues With New Nucleoside/Nucleotide Backbone Options (2004) (45)
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC‐resistant HIV‐1 reverse transcriptase (1996) (45)
Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection (2006) (45)
Mechanistic Studies of Early Pausing Events during Initiation of HIV-1 Reverse Transcription* (1998) (44)
Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal (2004) (44)
Changes in natural immunity during the course of HIV‐1 infection (1993) (44)
Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. (2014) (44)
Role of Stem B, Loop B, and Nucleotides next to the Primer Binding Site and the Kissing-Loop Domain in Human Immunodeficiency Virus Type 1 Replication and Genomic-RNA Dimerization (2001) (43)
Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. (2000) (43)
Logeracemin A, an anti-HIV Daphniphyllum alkaloid dimer with a new carbon skeleton from Daphniphyllum longeracemosum. (2014) (43)
Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy (1999) (43)
Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. (1998) (43)
Inactivation of human immunodeficiency virus type 1 in tissue culture fluid and in genital secretions by the spermicide benzalkonium chloride (1990) (42)
Effects of drug resistance on viral load in patients failing antiretroviral therapy (2006) (42)
Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina (2001) (42)
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). (1996) (42)
Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 (2003) (42)
Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. (1998) (42)
Infection of human monocytes/macrophages by HIV-1: effect on secretion of IL-1 activity. (1988) (42)
Deficient dimerization of human immunodeficiency virus type 1 RNA caused by mutations of the u5 RNA sequences. (2002) (41)
Factors Affecting Template Usage in the Development of K65R Resistance in Subtype C Variants of HIV Type-1 (2010) (41)
Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. (1990) (41)
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. (2003) (41)
What if HIV were unable to develop resistance against a new therapeutic agent? (2013) (41)
Effects of a Single Amino Acid Substitution within thep2 Region of Human Immunodeficiency Virus Type 1 on Packagingof Spliced ViralRNA (2003) (41)
Role of distal zinc finger of nucleocapsid protein in genomic RNA dimerization of human immunodeficiency virus type 1; no role for the palindrome crowning the R-U5 hairpin. (2001) (40)
The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities (2018) (40)
HIV Drug Resistance and the Advent of Integrase Inhibitors (2013) (40)
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination (2011) (40)
Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles (1999) (40)
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA (1996) (40)
Integrase strand transfer inhibitors in the management of HIV-positive individuals (2014) (40)
Lamivudine Can Exert a Modest Antiviral Effect against Human Immunodeficiency Virus Type 1 Containing the M184V Mutation (2003) (39)
Viral inhibition of lymphocyte mitogenesis: interference with the synthesis of functionally active T cell growth factor (TCGF) activity and reversal of inhibition by the addition of same. (1983) (39)
Role for Human Immunodeficiency Virus Type 1 Tat Protein in Suppression of Viral Reverse Transcriptase Activity during Late Stages of Viral Replication (2001) (39)
Mutations within Four Distinct Gag Proteins Are Required To Restore Replication of Human Immunodeficiency Virus Type 1 after Deletion Mutagenesis within the Dimerization Initiation Site (1999) (39)
Diminution of CD4 surface protein but not CD4 messenger RNA levels in monocytic cells infected by HIV-1. (1991) (39)
Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-kappaB/Rel pathway via enhanced IkappaBalpha degradation (1996) (38)
Multidrug-resistant variants of HIV type 1 (HIV-1) can exist in cells as defective quasispecies and be rescued by superinfection with other defective HIV-1 variants. (2009) (38)
Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. (2011) (38)
Future of Phylogeny in HIV Prevention (2013) (38)
Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort (2016) (37)
Leader Sequences Downstream of the Primer Binding Site Are Important for Efficient Replication of Simian Immunodeficiency Virus (2000) (37)
Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data (2011) (37)
NF-κB Protects HIV-1-Infected Myeloid Cells from Apoptosis (1998) (37)
Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine (2007) (37)
Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes (2010) (37)
NF-κB activation and HIV-1 induced apoptosis (1999) (37)
Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. (2016) (37)
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy? (2014) (37)
Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection (2009) (37)
Reconsidering the lifetime deferral of blood donation by men who have sex with men (2010) (36)
Will drug resistance against dolutegravir in initial therapy ever occur? (2015) (36)
Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? (1998) (36)
Plasminogen activator is an apparent lymphocyte mitogen. (1981) (36)
Didanosine Compared with Continued Zidovudine Therapy for HIV-Infected Patients with 200 to 500 CD4 Cells/mm3: A Double-Blind, Randomized, Controlled Trial (1995) (35)
Activation of cytokine genes in HIV-1 infected myelomonoblastic cells by phorbol ester and tumor necrosis factor. (1992) (35)
Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeat are required for efficient viral gene transcription. (1997) (35)
Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1 (1994) (35)
Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review (2014) (35)
Tetherin and Its Viral Antagonists (2011) (35)
Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men Receiving Rapid HIV Testing in Montreal, Canada (2016) (34)
Clinical correlates and molecular basis of HIV drug resistance. (1993) (34)
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. (2015) (34)
DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. (1994) (34)
AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. (1990) (33)
Impact of Human Immunodeficiency Virus Type 1 Subtype C on Drug Resistance Mutations in Patients from Botswana Failing a Nelfinavir-Containing Regimen (2006) (33)
Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1 (2017) (33)
Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome (1995) (33)
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors (1995) (33)
Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. (2009) (32)
Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. (2015) (32)
Deletion Mutagenesis within the Dimerization Initiation Site of Human Immunodeficiency Virus Type 1 Results in Delayed Processing of the p2 Peptide from Precursor Proteins (1999) (32)
Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain. (1993) (32)
In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1 (2007) (32)
Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. (2016) (31)
HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries. (2001) (31)
In Vitro Identification and Characterization of an Early Complex Linking HIV-1 Genomic RNA Recognition and Pr55Gag Multimerization* (2004) (31)
Differential Maintenance of the M184V Substitution in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Various Nucleoside Antiretroviral Agents in Tissue Culture (2004) (31)
Variable tRNA content in HIV-1IIIB. (1992) (31)
Cell-specific differences in activation of NF-kappa B regulatory elements of human immunodeficiency virus and beta interferon promoters by tumor necrosis factor (1990) (31)
HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug (2012) (31)
Gene expression profiling of the host response to HIV-1 B, C, or A/E infection in monocyte-derived dendritic cells. (2006) (31)
Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase (2015) (31)
An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHIEV2E Quality Control Study (2011) (31)
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription (1994) (31)
Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells. (1993) (30)
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir (2016) (30)
The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors (2018) (30)
Antiretroviral Therapy (2008) (30)
Reverse Transcriptase Inhibitors Can Selectively Block the Synthesis of Differently Sized Viral DNA Transcripts in Cells Acutely Infected with Human Immunodeficiency Virus Type 1 (1999) (30)
Antiviral activity and resistance profile of phosphazid--a novel prodrug of AZT. (1999) (29)
Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions (2015) (29)
Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection (2005) (29)
Flueggether A and Virosinine A, Anti-HIV Alkaloids from Flueggea virosa. (2015) (29)
The M230L Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation in HIV-1 Reverse Transcriptase Impairs Enzymatic Function and Viral Replicative Capacity (2010) (29)
Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. (2013) (29)
A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro annealing and exhibits multimerization-induced inhibition of reverse transcription. (2005) (28)
Induction of relA(p65) and I kappa B alpha subunit expression during differentiation of human peripheral blood monocytes to macrophages. (1997) (28)
Mechanisms of virus-induced immune suppression. (1985) (28)
Infection of human thymic lymphocytes by HIV-1. (1990) (28)
Viral inhibition of lymphocyte mitogenesis. I. Evidence for the nonspecificity of the effect. (1980) (28)
3′-Azido-3′-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants (1998) (27)
Infection of cultured human thymic epithelial cells by human immunodeficiency virus. (1989) (27)
Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec (2017) (27)
The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates (2003) (27)
The HIV-1 Vpu Viroporin Inhibitor BIT225 Does Not Affect Vpu-Mediated Tetherin Antagonism (2011) (27)
The effect of HIV-1 infection on the lipid fatty acid content in the membrane of cultured lymphocytes. (1990) (27)
Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase (2005) (26)
Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load (2012) (26)
Hydroxyurea in the Treatment of HIV Infection (2003) (26)
Generic HIV drugs--enlightened policy for global health. (2005) (26)
Limonoids with Anti-HIV Activity from Cipadessa cinerascens. (2015) (26)
Trichiconins A-C, limonoids with new carbon skeletons from Trichilia connaroides. (2014) (26)
Protection against guinea pig hepatomas by pretreatment with subcelluar fractions of Mycobacterium bovis (BCG). (1974) (26)
Infection of cultured human fetal pancreatic islet cells by rubella virus. (1989) (26)
Active replication of human immunodeficiency virus type 1 by peripheral blood mononuclear cells following coincubation with herpes viruses (1989) (26)
The Role of Antiretrovirals and Drug Resistance in Vertical Transmission of HIV‐1 Infection (2000) (26)
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. (2002) (26)
HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes (2010) (25)
Might dolutegravir be part of a functional cure for HIV? (2016) (25)
Investigation of the active center of trypsin using photochromic substrates. (1971) (25)
Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2 (2008) (25)
Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. (1998) (25)
Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. (1998) (25)
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus (2003) (24)
Resistance to HIV integrase inhibitors (2012) (24)
Analysis of Efficiency and Fidelity of HIV-1 (+)-Strand DNA Synthesis Reveals a Novel Rate-limiting Step during Retroviral Reverse Transcription* (2001) (24)
Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors (2014) (24)
Incorporation of tRNA into normal and mutant HIV-1. (1991) (24)
Novel, Live Attenuated Simian Immunodeficiency Virus Constructs Containing Major Deletions in Leader RNA Sequences (2001) (24)
Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds. (1995) (24)
Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. (2002) (24)
Mutations and Polymorphisms Associated with Antiretroviral Drugs in HIV-1C-Infected African Patients (2004) (24)
Construction and In Vitro Properties of a Series of Attenuated Simian Immunodeficiency Viruses with All Accessory Genes Deleted (2001) (24)
Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1 (2014) (24)
Effects of Infection by HIV‐1, Cytomegalovirus, and Human Measles Virus on Cultured Human Thymic Epithelial Cells (1989) (24)
Efficient Gap Repair Catalyzed In Vitro by an Intrinsic DNA Polymerase Activity of Human Immunodeficiency Virus Type 1 Integrase (1998) (24)
Molecular Mechanism of Antagonism between the Y181C and E138K Mutations in HIV-1 Reverse Transcriptase (2012) (23)
Infection by human cytomegalovirus and rubella virus of cultured human fetal islets of Langerhans. (1990) (23)
Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders. (1990) (23)
Prevalence of the K65R resistance reverse transcriptase mutation in different HIV‐1 subtypes in Israel (2009) (23)
Structure-Activity Relationships Among a New Class of Antiviral Heterosubstituted 2′,3′-Dideoxynucleoside Analogues (1995) (23)
Chemoprophylaxis of HIV infection: moving forward with caution. (2006) (23)
Deletion Mutagenesis Downstream of the 5′ Long Terminal Repeat of Human Immunodeficiency Virus Type 1 Is Compensated for by Point Mutations in both the U5 Region and gag Gene (2000) (23)
Non-specific effects of avian retrovirus co-incubation on lymphocyte function: abrogation of antigen- and mitogen-induced proliferative responsiveness. (1979) (23)
The effect of zidovudine on platelet count in HIV-infected individuals. (1990) (23)
A p6Pol-protease fusion protein is present in mature particles of human immunodeficiency virus type 1 (1996) (23)
Differential susceptibility of human lymphocyte cultures to infection by HIV. (1987) (22)
Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection (2010) (22)
Viral infection of human fetal islets of Langerhans. Replication of human cytomegalovirus in cultured human fetal pancreatic islets. (1988) (22)
Dominance of the E89G Substitution in HIV-1 Reverse Transcriptase in Regard to Increased Polymerase Processivity and Patterns of Pausing* (1998) (22)
Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR (1997) (22)
The effect of mutations in the HIV-1 nucleocapsid protein on strand transfer in cell-free reverse transcription reactions. (2000) (22)
Spliced human immunodeficiency virus type 1 RNA is reverse transcribed into cDNA within infected cells. (2004) (22)
AIDS: Drugs that prevent HIV infection (2011) (22)
Can the further clinical development of bevirimat be justified? (2010) (22)
HIV‐specific cytotoxic T‐lymphocyte activity in immunologically normal HIV‐infected persons (1998) (22)
Gender-sensitive reporting in medical research (2012) (22)
Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. (1994) (22)
Inhibition of HIV-1 transmission by interferon and 3'-azido-3'-deoxythymidine during de novo infection of promonocytic cells. (1990) (22)
Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. (1997) (21)
Multiple choices for HIV therapy with integrase strand transfer inhibitors (2012) (21)
Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products. (1998) (21)
Effect of HIV constructs containing protease‐reverse transcriptase fusion proteins on viral replication (1998) (21)
Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. (2003) (21)
Integrase Strand Transfer Inhibitors in HIV Therapy (2013) (20)
Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages (1993) (20)
Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. (2010) (20)
Identification of resveratrol analogs as potent anti‐dengue agents using a cell‐based assay (2017) (20)
HIV-1 Nucleocapsid Protein and the Secondary Structure of the Binary Complex Formed between tRNALys.3 and Viral RNA Template Play Different Roles during Initiation of (−) Strand DNA Reverse Transcription* (2001) (20)
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. (2010) (20)
Detection of zidovudine-resistant variants of HIV-1 in genital fluids. (1993) (20)
Subunit-Selective Mutational Analysis and Tissue Culture Evaluations of the Interactions of the E138K and M184I Mutations in HIV-1 Reverse Transcriptase (2012) (20)
Multi-Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge of Cynomolgus Macaques Immunized with “Hyperattenuated” SIV Constructs (2009) (20)
PL‐100, a novel HIV‐1 protease inhibitor displaying a high genetic barrier to resistance: An in vitro selection study (2008) (20)
Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C (2010) (20)
Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT‐Resistant Variants of HIV‐1 (1990) (20)
Cellular and humoral anti‐tumor immune responsiveness in chickens bearing tumors induced by avian sarcoma virus (1977) (20)
Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy (2017) (20)
Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine (1997) (20)
Development of cellular anti-tumor immunity in chickens bearing tumors induced by Rous sarcoma virus. (1977) (20)
Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity (2015) (20)
Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation. (2017) (20)
Inhibition by human T-lymphotropic virus (HTLV-I) of T-lymphocyte mitogenesis: failure of exogenous T-cell growth factor to restore responsiveness to lectin. (1985) (20)
Sensitivity and Resistance to (+)-Calanolide a of Wild-Type and Mutated Forms of HIV-1 Reverse Transcriptase (1998) (20)
Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1 (1997) (20)
Deletion of stem-loop 3 is compensated by second-site mutations within the Gag protein of human immunodeficiency virus type 1. (2003) (19)
Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase (2013) (19)
Handbook of Antimicrobial Resistance (2017) (19)
Anti-HIV Securinega alkaloid oligomers from Flueggea virosa (2015) (19)
Increased LAK activity against HIV‐infected cell lines in HIV‐1+ individuals (1992) (19)
Viral inhibition of lymphocyte proliferative responsiveness in patients suffering from recurrent lesions caused by herpes simplex virus. (1985) (19)
Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239 (2006) (19)
Suppression of an intrinsic strand transfer activity of HIV-1 Tat protein by its second-exon sequences. (2003) (19)
Transcription of Preintegrated HIV-1 cDNA Modulates Cell Surface Expression of Major Histocompatibility Complex Class I via Nef (2011) (19)
Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to Etravirine (2009) (18)
New cd4( +) cell line susceptible to infection by hiv‐1 (1989) (18)
Envelope V3 region sequences of Cuban HIV-1 isolates. (1995) (18)
Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIV. (2014) (18)
Altered constitutive and stress-regulated heat shock protein 27 expression in HIV type 1-infected cell lines. (1995) (18)
Perspectives on antiviral drug development. (2009) (18)
Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1. (1998) (18)
Latent HIV-1 Can Be Reactivated by Cellular Superinfection in a Tat-Dependent Manner, Which Can Lead to the Emergence of Multidrug-Resistant Recombinant Viruses (2013) (18)
Further studies on the mitogenic and immune-modulating effects of plasminogen activator. (1982) (18)
Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the initiation step of reverse transcription in human immunodeficiency virus type 1. (2000) (17)
Infection of human thymic epithelial cells by human cytomegalovirus and other viruses: effect on secretion of interleukin 1-like activity. (1988) (17)
Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. (2013) (17)
Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir (2013) (17)
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). (2005) (17)
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors. (2012) (17)
Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane. (1999) (17)
Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report (2008) (17)
M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA (2017) (17)
Thymic dependence of cell-mediated immunity to avian sarcomas in chickens. Immunological characterization of a nonvirion antigen in virus-infected cells. (1979) (17)
Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS. (1994) (17)
Translation of Pr55(gag) augments packaging of human immunodeficiency virus type 1 RNA in a cis-acting manner. (2002) (16)
Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro. (1999) (16)
The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance (2015) (16)
New Securinega alkaloids with anti-HIV activity from Flueggea virosa (2015) (16)
Early immune adaptation in HIV-1 revealed by population-level approaches (2014) (16)
Decreased production of transforming virus and altered antigenic behaviour in cultured avian sarcoma cells. (1979) (16)
Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency (2014) (16)
Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice (2017) (16)
The roles of the human immunodeficiency virus type 1 Pol protein and the primer binding site in the placement of primer tRNA(3Lys) onto viral genomic RNA (1997) (16)
The Role of CD4 and its Downmodulation in Establishment and Maintenance of HIV‐1 Infection (1994) (15)
Inhibition of NF‐&kgr;B‐dependent HIV‐1 replication by the marine natural product bengamide A (2018) (15)
A Significant Reduction in the Frequency of HIV-1 Drug Resistance in Québec from 2001 to 2011 Is Associated with a Decrease in the Monitored Viral Load (2014) (15)
Differential susceptibilities of U-937 cell clones to infection by human immunodeficiency virus type 1 (1992) (15)
Differential regulation of CC chemokine gene expression in human immunodeficiency virus-infected myeloid cells. (1999) (15)
Recovery of infectious human immunodeficiency virus type 1 after fusion of defectively infected clones of U-937 cells (1991) (15)
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance (2012) (15)
Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor (2015) (15)
Investigational HIV integrase inhibitors in phase I and phase II clinical trials (2017) (15)
Replication of Human Immunodeficiency Viruses Engineered with Heterologous Tat-Transactivation Response Element Interactions (2003) (15)
Pressure of Zidovudine Accelerates the Reversion of Lamivudine Resistance-Conferring M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 (2002) (15)
Apricitabine: A Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection (2007) (15)
Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1. (2013) (14)
Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection. (2008) (14)
Current Insights into Reverse Transcriptase Inhibitor-Associated Resistance (2000) (14)
Flueggethers B–D, Securinega alkaloids with rare oligomerizing pattern from Flueggea virosa (2016) (14)
Need for caution in interpretation of Western Blot tests for HIV. (1987) (14)
High levels of IgE in patients suffering from frequent recurrent herpes simplex lesions. (1986) (14)
Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications. (1998) (14)
NF-kappaB protects HIV-1-infected myeloid cells from apoptosis. (1998) (14)
Hydrophobic Amino Acids in the Human Immunodeficiency Virus Type 1 p2 and Nucleocapsid Proteins Can Contribute to the Rescue of Deleted Viral RNA Packaging Signals (2001) (14)
Interactions between human immunodeficiency virus type 1 reverse transcriptase, tRNA primer, and nucleocapsid protein during reverse transcription. (2000) (14)
Characterization of Antiviral Activity of Benzamide Derivative AH0109 against HIV-1 Infection (2013) (14)
Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity (2015) (14)
Role of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and Other Nonnucleoside Reverse Transcriptase Inhibitors (2013) (14)
A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence. (2012) (14)
Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations. (1991) (14)
Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies. (1990) (14)
Immune selection of tumor cell variants in chickens bearing tumors induced by avian sarcoma virus. (1982) (14)
Analysis of Primer Extension and the First Template Switch during Human Immunodeficiency Virus Reverse Transcription. (1995) (14)
Antibody-Dependent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers. (2016) (14)
A resveratrol analog termed 3,3′,4,4′,5,5′‐hexahydroxy‐trans‐stilbene is a potent HIV‐1 inhibitor (2015) (14)
Development of an Allele-Specific PCR for Detection of the K65R Resistance Mutation in Patients Infected with Subtype C Human Immunodeficiency Virus Type 1 (2009) (14)
Time for gender mainstreaming in editorial policies (2011) (13)
Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers. (2000) (13)
HIV-1 Drug Resistance (2002) (13)
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration (2017) (13)
Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. (2002) (13)
Update on rilpivirine: A new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication (2013) (13)
The M184V Mutation in Reverse Transcriptase Can Delay Reversion of Attenuated Variants of Simian Immunodeficiency Virus (2002) (13)
The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity (2013) (13)
Desferrioxamine and HIV (1991) (13)
Selection of TAR RNA-Binding Chameleon Peptides by Using a Retroviral Replication System (2004) (13)
Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy (2015) (13)
The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir (2015) (13)
Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness (2012) (13)
Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. (1988) (13)
The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B (2015) (13)
Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1 (2005) (12)
Effect of -propiolactone on Sendai virus. (1971) (12)
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine. (1998) (12)
Inhibition of Human Immunodeficiency Virus Type-1 (HIV-1) Replication by Immunor (Im28), a New Analog of Dehydroepiandrosterone (2000) (12)
Insulin-like growth factor 1 and insulin inhibit HIV type 1 replication in cultured cells. (1995) (12)
Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations (2009) (12)
Viral abrogation of lymphocyte mitogenesis: induction of a soluble factor inhibitory to cellular proliferation. (1980) (12)
Achieving the 90-90-90 target: incentives for HIV testing. (2016) (12)
Harnessing the therapeutic potential of host antiviral restriction factors that target HIV (2013) (12)
Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1 (1996) (11)
Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants Resistant to the (+) and (−) Enantiomers of 2′-Deoxy-3′-Oxa-4′-Thio-5-Fluorocytidine (2000) (11)
Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes (2018) (11)
Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference (2017) (11)
Kinetics of Inhibition of HIV Type 1 Reverse Transcriptase-Bearing NRTI-associated Mutations by Apricitabine Triphosphate (2007) (11)
HIV–1 resistance to dolutegravir: update and new insights (2015) (11)
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound (2014) (11)
Antiviral activity and protection of cells against human immunodeficiency virus type-1 using an antisense oligodeoxyribonucleotide phosphorothioate complementary to the 5'-LTR region of the viral genome. (1995) (11)
Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity (2015) (11)
Increased soluble tumor necrosis factor receptor expression and release by human immunodeficiency virus type 1 infection. (1995) (11)
Host Cell Dependence of Human Immunodeficiency Virus Type-1 Drug Resistance Profiles and Tissue Culture Selection Patterns (1995) (11)
Reversible interference with TCGF activity by virus particles. (1984) (11)
Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses (2016) (11)
Non-specific inhibition by virus particles of human lymphocytes mitogenesis. (1980) (11)
Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load (1997) (11)
Immunity against avian sarcomas: a review. (1976) (11)
The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors (1996) (11)
Generation and characterization of murine monoclonal antibodies reactive against N‐terminal and other regions of HIV‐1 reverse transcriptase (1993) (10)
Dolutegravir inhibits HIV-1 Env evolution in primary human cells (2015) (10)
HIV-1 reverse transcriptase shows no specificity for the binding of primer tRNA(Lys3). (1996) (10)
The emergence of HIV resistance and new antiretrovirals: are we winning? (2004) (10)
Virus induction of NF-kappa B/Rel proteins and type I interferon gene expression in myelomonoblastic cells. (1994) (10)
Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations. (1992) (10)
Compensation by the E 138 K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M 184 I / V Mutations (2011) (10)
Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention (2013) (10)
Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens (2009) (10)
Selection of Resistance-Conferring Mutations in HIV-1 by the Nucleoside Reverse Transcriptase Inhibitors (+/-)dOTC and (+/-)dOTFC (2000) (10)
Strategies for the optimal sequencing of antiretroviral drugs toward overcoming and preventing drug resistance (2007) (10)
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration (2017) (10)
The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA. (2005) (10)
The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells. (2003) (10)
The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir (2014) (10)
Inhibition of human lymphocyte mitogenesis by human and other retroviruses. Differential effect of interleukin-2 in restoration of responsiveness. (1987) (10)
Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation. (2011) (10)
Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1. (1994) (10)
Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can interfere with processing and viral replication. (1998) (10)
Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries (2008) (10)
Differential expression of relevant Rous sarcoma-associated antigens in cultured cells. (1977) (9)
Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review. (2007) (9)
JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1 (2017) (9)
Variability in the PR and RT Genes of HIV-1 Isolated from Recently Infected Subjects (2004) (9)
Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients. (1996) (9)
NF-kappaB activation and HIV-1 induced apoptosis. (1999) (9)
HIV transmission should be decriminalized: HIV prevention programs depend on it (2008) (9)
Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors (2015) (9)
The effects of T-cell growth factor and virus purification on virus-mediated inhibition of lymphocyte mitogenesis. (1982) (9)
Roles of Pr 55 gag and NCp 7 in tRNA 3 Lys Genomic Placement and the Initiation Step of Reverse Transcription in Human Immunodeficiency Virus Type 1 (2000) (9)
Quantitative assessment of the effect of cyproheptadine on spastic paretic gait: a preliminary study (1986) (9)
Synthesis, lipophilicity and anti-HIV activity of a new brominated analog of zidovudine. (1999) (9)
Evolutionary mechanisms of retroviral persistence. (2011) (9)
Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor (2015) (9)
Effects of dexamethasone on antigen expression and virus production in avian sarcoma virus-transformed cells. (1982) (9)
The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin (1991) (9)
HIV-1 Group O Resistance Against Integrase Inhibitors (2015) (9)
Effects of RU486 on HIV-1 replication (1997) (9)
The Role of Surrogate Markers in the Clinical Development of Antiretroviral Therapy: A Model for Early Evaluation of Targeted Cancer Drugs (2004) (9)
HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters (2017) (9)
Human Immunodeficiency Virus Proviral DNA from Peripheral Blood and Lymph Nodes Demonstrates Concordant Resistance Mutations to Zidovudine (Codon 215) and Didanosine (Codon 74) (1998) (9)
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients (2017) (8)
Multiple forms of tRNA(Lys3) in HIV-1. (1996) (8)
Infection of human monocyte‐derived macrophages by human immunodeficiency virus mediated by cell‐to‐cell transmission (1993) (8)
Differential susceptibility of avian sarcoma cells derived from different periods of tumor growth to natural killer cell activity. (1983) (8)
The need to promote public health in the field of illicit drug use (2006) (8)
Kinetics of HIV-1 CTL Epitopes Recognized by HLA I Alleles in HIV-Infected Individuals at Times near Primary Infection: The Provir/Latitude45 Study (2014) (8)
Effect of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes (1994) (8)
Enhancement of avian sarcoma virus-induced tumor growth after pretreatment with BCG (1978) (8)
Insights into HIV-1 pathogenesis through drug discovery: 30 years of basic research and concerns for the future (2011) (8)
HIV-1 Subtype Variability in Vif Derived from Molecular Clones Affects APOBEC3G-Mediated Host Restriction (2013) (8)
Nonradioactive detection of retroviral-associated RNase H activity in a microplate-based, high-throughput format. (2002) (8)
A new class of HIV-1 inhibitors and the target identification via proteomic profiling (2018) (8)
Specific stimulation of lymphocytes from patients with AIDS by herpes simplex virus antigens. (1987) (8)
Diminished HIV-1 Sensitivity to Stavudine in Patients on Prolonged Therapy Occurs Only at Low Levels and Cannot be Attributed to Any Single Amino Acid Substitution in Reverse Transcriptase (1998) (8)
Criminalizing HIV transmission may be a mistake (2009) (8)
Virus-mediated abrogation of chicken lymphocyte responsiveness to mitogenic stimulus. (1980) (8)
Infection-Mediated Resistance to Cell Fusion by Inactive Sendai Virus 1 (1973) (8)
The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. (2015) (8)
Expression, purification, and RNA-binding properties of HIV-1 p15gag nucleocapsid protein. (1993) (8)
Correlation between high level gp160 expression and reduced CD4 biosynthesis in clonal derivatives of human immunodeficiency virus type 1-infected U-937 cells. (1994) (8)
Human immunodeficiency virus type 1 integrase stabilizes a linearized HIV-1 LTR plasmid in vivo. (1995) (8)
Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs (2018) (8)
Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. (2015) (8)
Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs (2005) (8)
Human Immunodeficiency Virus Type 1-Associated Cd4 Downmodulation (1994) (8)
XMRV as a Human Pathogen? (2011) (8)
Two standards of care for HIV: Why are Africans being short-changed? (2009) (7)
We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance. (2016) (7)
Estimates of the virological benefit of antiretroviral therapy are both assay‐ and analysis‐dependent (1998) (7)
Selection and Characterization of HIV-1 Variants Resistant to the (+) and (-) Enantiomers of 2′-Deoxy-3′-Oxa-4′-Thiocytidine (Dotc) (1998) (7)
HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations. (2013) (7)
Proceedings of the Frontiers of Retrovirology Conference 2016 (2016) (7)
HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase (2014) (7)
Place of antiretroviral drugs in the treatment of HIV-infected people in Africa. International AIDS Society. (1999) (7)
First report of HIV-2 infection in Argentina. (1998) (7)
Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239 (2015) (7)
Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors. (2011) (7)
[HIV drug resistance and optimization of antiviral treatment in resource-poor countries]. (2004) (7)
Viral inhibition of lymphocyte mitogenesis: the role of macrophages as primary targets of virus-cell interaction. (1981) (7)
Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study (2017) (7)
Replication of measles virus in cultured human thymic epithelial cells (1989) (7)
Zidovudine‐resistant and -sensitive HIV‐1 isolates from patients on drug therapy: in vitro studies evaluating level of replication‐competent viruses and cytopathogenicity (1992) (7)
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. (2018) (7)
Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing (2004) (7)
Mature reverse transcriptase (p66/p51) is responsible for low levels of viral DNA found in human immunodeficiency virus type 1 (HIV-1). (1994) (6)
Human T-Cell Retrovirus and Adult T-Cell Lymphoma and Leukemia: Possible Factors on Viral Incidence (1983) (6)
Clinical significance and characterization of AZT-resistant strains of HIV-1. (1991) (6)
Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate. (1995) (6)
A new source of resistance to HIV drugs. (1999) (6)
Inhibition of human immunodeficiency virus type 1 multiplication by transforming growth factor beta 1 and AZT in HIV-1-infected myeloid cells. (1995) (6)
Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome (2007) (6)
Involvement of macrophage-like cells in growth of tumors induced by avian sarcoma virus. (1983) (6)
Sequences Downstream of the 5′ Splice Donor Site Are Required for both Packaging and Dimerization of Human Immunodeficiency Virus Type 1 RNA (2003) (6)
Sugar transport and glut transporter expression in a variety of human immunodeficiency virus-1 (HIV-1) chronically infected target cell lines. (1998) (6)
Factors Affecting Cell Fusion Induced by Sendai Virus (1973) (6)
Cessation of zidovudine therapy may lead to increased replication of HIV-1. (1989) (6)
HIV resistance to antiviral drugs: public health implications. (1998) (6)
HIV and Ebola: similarities and differences (2014) (6)
How will the ebola crisis impact the HIV epidemic? (2014) (6)
Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada. (2008) (6)
Logeracemin A, an anti‐HIV Daphniphyllum Alkaloid Dimer with a New Carbon Skeleton from Daphniphyllum longeracemosum. (2014) (6)
Replication of cytomegalovirus in human thymic epithelial cells (2004) (6)
Partial Restoration of Replication of Simian Immunodeficiency Virus by Point Mutations in either the Dimerization Initiation Site (DIS) or Gag Region after Deletion Mutagenesis within the DIS (2001) (6)
The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites. (2013) (5)
Will LEDGIN molecules be able to play a role in a cure for HIV infection? (2016) (5)
HIV Resistance to Antagonists of Viral Reverse Transcriptase (1999) (5)
Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial (2018) (5)
Stimulation of anti-tumour immunity in guinea-pigs by methanol extraction residue of BCG (1976) (5)
Immunological responsiveness against tumors induced by avian sarcoma virus: reduced expression of pp60src kinase activity in regressing tumors (1985) (5)
Direct involvement of extracellular HIV-1 virions in the apoptosis of CD8+ lymphocytes: a two-step model. (1994) (5)
Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. (2010) (5)
Antibody-mediated fusion of FL amnion cells infected with parainfluenza virus type 2. (1972) (5)
Immune stimulation of sensitized chicken lymphocytes by avian retrovirus proteins. (1982) (5)
Opportunistic infections and CD4+ T-lymphocytopenia without HIV infection: report of two cases. (1993) (5)
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection (1995) (5)
Subtype-Specific Analysis of the K65R Substitution in HIV-1 That Confers Hypersusceptibility to a Novel Nucleotide-Competing Reverse Transcriptase Inhibitor (2015) (5)
Phenotypic differences between tumor cells derived from different stages of neoplastic growth. (1982) (5)
Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase (2014) (5)
Avian Sarcomas: Immune Responsiveness and Pathology (1986) (5)
Susceptibility to AZT of HIV-1 variants grown in Epstein-Barr virus-transformed B cell lines. (1989) (5)
A Plea for Justice for Jailed Medical Workers (2006) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
False-positive results of confirmatory testing for antibody to HIV-I. (1987) (5)
Nutriceutical Modulation of Glutathione with a Humanized Native Milk Serum Protein Isolate, IMMUNOCAL™ : Application in AIDS and Cancer : IMMUNOCAL™: (1997) (5)
Exposure to Entry Inhibitors Alters HIV Infectiousness and Sensitivity to Broadly Neutralizing Monoclonal Antibodies (2014) (5)
Expression of the somatostatin gene in human astrocytoma cell lines (1996) (4)
HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity (2017) (4)
The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. (1991) (4)
Early HIV treatment to forestall drug resistance. (2016) (4)
Lack of Effect of Recombinant Human Growth Hormone on the In Vitro Activities of Antiretroviral Drugs against Human Immunodeficiency Virus Type 1 (2004) (4)
Inhibition by AZT of HIV‐1 Replication in Acutely Infected U‐937 Cells (1990) (4)
Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome. (2015) (4)
The impact of the journalist-to-journalist program on worldwide HIV awareness. (2008) (4)
Neutralization of pseudotypes of vesicular stomatitis virus by sera from avian retrovirus‐infected hosts (1979) (4)
ENHANCEMENT OF SENDAI VIRUS-MEDIATED CELL FUSION BY CUPRIC IONS (1973) (4)
The need for microbicides: why aren't women's groups more involved in the fight against AIDS? (1999) (4)
Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review (2016) (4)
Four new lignans from the leaves and stems of Schisandra propinqua var. sinensis (2013) (4)
Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc (2014) (4)
Different effects of breast cancer, HIV-1 infection and chemotherapy on inducible natural immunity. (1994) (4)
Preferential lymphocyte-mediated cytotoxicity of syngeneic target cells in chickens bearing tumors induced by avian sarcoma virus. (1985) (4)
Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic (2014) (4)
Effect of insulin-like growth factor I on HIV type 1 long terminal repeat-driven chloramphenicol acetyltransferase expression. (1999) (4)
Women hold up half the sky – and half the burden of the HIV epidemic (2013) (4)
Targeting HIV reverse transcriptase in novel ways (1995) (4)
Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines (2014) (4)
Inducible Expression of I k B a Repressor Mutants Interferes with NF- k B Activity and HIV-1 Replication in Jurkat T Cells* (1998) (3)
The 16th International Conference on AIDS: Will It Leave a Legacy? (2007) (3)
Expression of avian sarcoma virus genes in tumor cells derived from different periods of tumor growth. (1987) (3)
Tetherin restricts direct cell-cell viral transfer and transmission of HIV-1 (2010) (3)
Host immunity and the course of HIV infection. (1993) (3)
Criminalization of HIV Transmission : 135 Actually (2013) (3)
Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2. (1994) (3)
The International Conference on AIDS. Why we chose South Africa. (1999) (3)
Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation. (2010) (3)
HIV‐1 associated down‐modulation of CD4 gene expression is differentially restricted in lymphocytic and monocytic cell lines (1994) (3)
Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy. (1992) (3)
Impact of the 16th International Conference on AIDS: can these conferences lead to policy change? (2007) (3)
Resistance Profile of a Novel 2′, 3′ - Dideoxynucleoside Analog with Activity Against HIV-1 (1997) (3)
Characterization of zidovudine resistant variants of HIV-1 isolated from patients on prolonged therapy. (1992) (3)
New pandemics: HIV and AIDS, HCV and chronic hepatitis, Influenza virus and flu (2007) (3)
Effect of co-incubation with cytomegalovirus on growth of interleukin 2-dependent lymphocytes. (1988) (3)
Short communication: antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire. (2013) (3)
Stimulation of anti-tumour immunity in guinea-pigs by methanol extraction residue of BCG. (1976) (3)
HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase. (2009) (3)
A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada (2017) (3)
Differential effect of the immunomodulatory hormone somatostatin on replication of human immunodeficiency virus type 1 in CD4+ and CD8+ T lymphocytes (1995) (3)
Effects of the W153L Substitution in HIV Reverse Transcriptase on Viral Replication and Drug Resistance to Multiple Categories of Reverse Transcriptase Inhibitors (2014) (3)
Differential responsiveness of various substrains of inbred strain 2 guinea pigs to immunotherapy with the methanol extraction residue (MER) of BCG (1977) (2)
Vertical transmission of tumour resistance in guinea pigs (1976) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Non-Nucleoside Inhibitors of HIV Reverse Transcriptase (2003) (2)
Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group. (1998) (2)
In Tribute to Joep Lange (2014) (2)
COX (2020) (2)
Pre-exposure prophylaxis against HIV: pros and cons (2012) (2)
Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease. (2009) (2)
Inhibition of CD4 Translation Mediated by Human Immunodeficiency Virus Type 1 Envelope Protein in a Cell-free System* (1997) (2)
Journal of the International AIDS Society: an important step forward (2008) (2)
Pending problem of "silent" human immunodeficiency virus infection. (1995) (2)
HIV resistance to anti-viral drugs. (1993) (2)
The global need for microbicides (2001) (2)
[Mechanisms of reduction of CD4 receptor expression on the surface of HIV-1 infected cells]. (1996) (2)
The long-term effects of anti-retroviral protease inhibitors on sugar transport in L 6 cells (2003) (2)
Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of Dengue virus replication# (2017) (2)
Heterogeneity of HIV-1 replication and antigen expression in EBV-transformed B cell lines. (1988) (2)
HIV-1 subtype C viruses rapidly develop K65R (2006) (2)
An Intact U5-Leader Stem Is Important for Efficient Replication of Simian Immunodeficiency Virus (2001) (2)
The First Report of HIV-1 Group O Infection in Canada (2014) (2)
HIV-1 Resistance to Integrase Inhibitors (2017) (2)
Antiviral drug development (2011) (2)
Controlling elements in replication of the human immunodeficiency virus type 1. (1997) (2)
Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively (1996) (2)
Heat Shock Protein-Based Therapeutic Strategies Against Human Immunodeficiency Virus (1999) (2)
HIV-1 subtype B integrase confers low-level (2014) (2)
Maturation of human fetal and infantile thymic cells in tissue culture. (1989) (2)
Presence of insulin binding sites on viral particles. (1988) (2)
The endless tragedy of pediatric AIDS. (1999) (2)
Effect of prior inoculation with chemical carcinogens on development of avian retrovirus-induced neoplasia in chickens. (1980) (2)
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M (2014) (2)
The role of interleukins in viral inhibition of lymphocyte mitogenesis. (1985) (2)
Afri-Can Forum 2 (2016) (2)
Anti-retroviral strategies for AIDS and related diseases. (1991) (2)
Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region. (2017) (2)
In HIV‐infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine (1994) (1)
Microbicides 2000 conference. Welcoming remarks. The global need for microbicides. (2001) (1)
South Africa must admit that HIV/AIDS is its greatest enemy (1999) (1)
Ten big challenges ahead (2014) (1)
Population-level phylogenetic surveillance of the Montreal men who have sex with men epidemic 2002–12 (2013) (1)
Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout (2018) (1)
Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity (2013) (1)
Inhibitors Rilpivirine and Etravirine Nonnucleoside Reverse Transcriptase Defining Patterns of Resistance to Interactions with the M184I Mutation on HIV-1 Reverse Transcriptase and Their Effect of Mutations at Position E138 in (2014) (1)
Obituary: Kuan-Teh Jeang (2013) (1)
VIRAL IHIBITION OF LYMPHOCYTE MITOGENESIS: IMMUNOLOGICAL CHARACTERIZATION OF AN INHIBITORY FACTOR DERIVED FROM ADHERENT CELLS (1980) (1)
World AIDS Day 2015 (2015) (1)
Desensitization of effective anti-turmour immunity in guinea pigs. (1977) (1)
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness (2014) (1)
Mechanistic study of BST-2 down-modulation by HIV-1 Vpu (2009) (1)
The XVI International Conference on AIDS: The place to be! (2006) (1)
Biochemical mechanism of clinical resistance to rilpivirine (2012) (1)
Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs. (2005) (1)
The 20th International AIDS Conference: where do we go from here? (2014) (1)
Toward control of electron transfer in donor-acceptor molecules by bond-specific infrared excitation (2014) (1)
Resistance against inhibitors of HIV-1 entry into target cells (2015) (1)
Latent HIV-1 can be reactivated by superinfection in a Tat-dependent manner, which can lead to the emergence of recombinant viruses (2013) (1)
A HIV-1 Minimal Gag Protein Is Superior to Nucleocapsid at in Vitro \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\mathrm{tRNA}_{3}^{\mathrm{Lys}}\) \end{document} Annealing and Exhibits (2005) (1)
Interactions of different drug resistance mutations in HIV Reverse Transcriptase in defining patterns of drug resistance (2011) (1)
Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase (2014) (1)
Nucleoside Inhibitors of HIV Reverse Transcriptase and the Problem of Drug Resistance (2021) (1)
Multiple choices for HIV therapy with integrase strand transfer inhibitors (2012) (1)
World AIDS Day: together we will stop HIV transmission and conquer AIDS (2013) (1)
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure (2013) (1)
Why are there so many myths about AIDS? (1993) (1)
CHAPTER 14 – Development and Transmission of HIV Drug Resistance (2008) (1)
Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine. (1999) (1)
Correction for Wilson et al., The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics (2009) (1)
Effect of glucosamine on virus production and antigen expression in avian sarcoma virus-transformed cells. (1978) (1)
Clinical Significance and Biological Basis of HIV Drug Resistance (2008) (1)
Latent HIV-1 can be reactivated by superinfection in a Tat-dependent manner, which can lead to the emergence of recombinant viruses (2013) (1)
Transmission of BCG-associated tumor resistance from maternal to newborn guinea pigs. (1976) (1)
HIV Drug Resistance: Molecular Basis and Clinical Significance (1995) (1)
HIV and Zika: When will we be able to end these epidemics? (2016) (1)
Monsef Benkirane awarded 2013 Ming K. Jeang Foundation Retrovirology Prize: Landmark HIV-1 research honoured (2013) (1)
Public funding for AIDS research in Canada and the USA. (1986) (1)
In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor. (2013) (1)
AIDS research funding in Canada: future directions and government policy. (1991) (1)
Enhanced viral inhibition of lymphocyte mitogenesis in patients with advanced breast cancer. (1985) (1)
World AIDS Day: together we will stop HIV transmission and conquer AIDS (2013) (1)
New Securinega Alkaloids with anti-HIV Activity from Flueggea virosa. (2016) (1)
The role and fate of the CD4 molecule in lymphocytes and monocytes infected by HIV-1. (1993) (1)
Alteration of phenotype of 'regressor' avian sarcoma cells following treatment with phorbol ester. (1983) (1)
Proof of principle: antiretroviral drugs can prevent sexual transmission of HIV-1 (2011) (1)
A sequence analysis of the primer binding site (PBS) region of the RNA genome of simian and human immunodeficiency viruses (SIV and HIV) (1998) (1)
Effect of cytomegalovirus on lectin-driven mitogenesis of human thymic and peripheral blood lymphocytes. (1988) (1)
Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines. (2009) (1)
Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes. (2010) (1)
The M 184 V Mutation in Reverse Transcriptase Can Delay Reversion of Attenuated Variants of Simian Immunodeficiency Virus (2002) (1)
A HIV-1 Minimal Gag Protein Is Superior to Nucleocapsid at in Vitro tRNA3 (2005) (1)
HIV-1 recombinant reverse transcriptase enzymes containing the G 190 A and Y 181 C resistance mutations remain sensitive to etravirine (2009) (1)
LONG TERM FOLLOW-UP OF A DOUBLE BLIND STUDY OF ddI vs CONTINUED AZT AMONG INDIVIDUALS WITH CD4s 200???500/mm3 (1994) (1)
Early immune adaptation in HIV-1 revealed by population-level approaches (2014) (1)
Global perspective from International AIDS Society president Mark Wainberg. Interview by Dennis Blakesley. (1998) (1)
Monsef Benkirane awarded 2013 Ming K. Jeang Foundation Retrovirology Prize: Landmark HIV-1 research honoured (2013) (1)
Effect of phorbol ester on growth of tumors induced by Rous sarcoma virus and on pp60src kinase activity in these tumors. (1987) (1)
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency (2013) (1)
Antiviral drug development: progress and pitfalls (2008) (0)
Rilpivirine Is a Potent Novel Non-Nucleoside Reverse Transcriptase Inhibitor of HIV Replication (2012) (0)
Reviewer acknowledgement 2014 (2015) (0)
Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration” (2018) (0)
[Immunological and structural properties of Rous sarcoma virus-transformed and tumor cells]. (1978) (0)
Biological Basis and Clinical Significance of HIV Resistance to Antiviral Drugs (2008) (0)
I-103 The absence of drug resistance against dolutegravir in first-line therapy is attributable to reduced viral replicative fitness (2017) (0)
STRATEGIES D'INTERFERENCES AVEC LA REPLICATION DU VIRUS D'IMMUNODEFICIENCEHUMAINE (1992) (0)
Significance of the L74V mutation in HIV-1 reverse transcriptase (2006) (0)
Retroviral Biodiversity: Practical Consequences for HIV Treatment and Prevention (2008) (0)
Flueggethers B-D, Securinega Alkaloids with Rare Oligomerizing Pattern from Flueggea virosa. (2016) (0)
MECHANISTIC STUDIES OF NUCLEOSIDE RESISTANCE INVOLVING RECOMBINANT PURIFIED HIV REVERSE TRANSCRIPTASE (1994) (0)
Inhibitors of the Human Immunodeficiency Virus Protease (2009) (0)
Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention (2013) (0)
Correction for Anstett et al., “HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity” (2018) (0)
Structure-Activity Relationships Among a New Class of Antiviral Heterosubstituted 2′,3′-Dideoxynucleoside Analogues. (2010) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
eJIAS: Editor's Welcome (2004) (0)
Criminalization of HIV Transmission By : (2013) (0)
Drug therapy in HIV infection--fourth international congress. 8-12 November 1998, Glasgow, Scotland. (1999) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
162 Transmission Networks of Drug Resistance Acquired in Primary/Early Stage HIV Infection (2009) (0)
HIV entry blocked by maraviroc can cause an overestimation of viral load (2010) (0)
Reviewer acknowledgement 2013 (2014) (0)
Interview with Professor Mark A Wainberg (2016) (0)
Identification of novel HIV-1 integrase inhibitors with excellent resistance profiles from natural products (2013) (0)
In Vitro Antiviral Activity and Cross-Resistance Proﬁle of PL-100, a Novel Protease Inhibitor of Human Immunodeﬁciency Virus Type 1 (cid:1) (2007) (0)
Fifth International Conference on AIDS : the Scientific and Social Challenge; symposium; laboratory issues in the diagnosis of AIDS (1989) (0)
REVERSAL BY T CELL GROWTH FACTOR OF VIRAL INHIBITION OF LYMPHOCYTE MITOGENESIS (1982) (0)
Studies on interactions between plasminogen activator-containing fluids and avain and murine lymphocytes. (1981) (0)
Twenty-five years of AIDS: where are we now? (2006) (0)
Maraviroc in Early HIV Disease (2008) (0)
Combined phylogenetic and epidemiological analyses predict factors fuelling the male-sex-male epidemic in Quebec (2010) (0)
Biochemical and virological analysis of the preference for the K65R multi-resistance nucleoside mutation in subtype C viruses (2009) (0)
Trichiconins A—C, Limonoids with New Carbon Skeletons from Trichilia connaroides. (2015) (0)
Flueggether A and Virosinine A, anti‐HIV Alkaloids from Flueggea virosa. (2016) (0)
OPINION Evolution of HIV integrase resistance mutations (2012) (0)
Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse 1 (2012) (0)
Reviewer acknowledgement 2015 (2016) (0)
BOUND STATE SOLUTIONS OF SCHRÖDINGER EQUATION FOR A MORE GENERAL EXPONENTIAL SCREENED COULOMB POTENTIAL VIA NIKIFOROV- UVAROV METHOD (2010) (0)
Structural changes in the SL5 and SL6 leader sequences of HIV-1 RNA following interactions with the viral mGag protein. (2011) (0)
World AIDS Day 2015 (2015) (0)
Epidemiology and Evolution of Antiretroviral Drug Resistance (2005) (0)
Specific Redistribution Effect that Results in Increased (2012) (0)
A 11 Patent Number : 5 , 837 , 257 ( 45 ) Date of Patent : Nov . 17 , 1998 54 USE OF PLANT EXTRACTS FOR TREATMENT OF HIV , HCV AND HBV INFECTIONS (0)
eJIAS: Editor's Welcome. (2004) (0)
Differential effects of phorbol ester on tumor cells induced by avian sarcoma virus. (1987) (0)
Studies on pp60src and associated kinase activity in regressing tumors induced by Rous sarcoma virus. (1987) (0)
Biochemical evidence of HIV-1 subtype B and C different patterns of resistance to integrase inhibitors (2010) (0)
differential development of resistance to nelfinavir, lopinavir and atazanavir in different (2010) (0)
Effect of mutations in NC7 on endogenous reverse transcription in HIV-1 (1999) (0)
Proceedings of the Frontiers of Retrovirology Conference 2016 (2016) (0)
The effects of the W 153 L substitution in HIV reverse transcriptase on viral replication and 1 drug resistance to multiple categories of reverse transcriptase inhibitors 2 (2014) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Effect of β-Propiolactone on Sendai Virus (1971) (0)
Resistance Substitutions in HIV-1 Integrase G118R-Linked Dolutegravir Drug Biochemical Analysis of the Role of (2014) (0)
Biological Basis for Preferential Selection of the K65R Mutation in HIV Subtype C (2008) (0)
Virus Type 1 Transcription in Human Immunodeficiency Placement and Initiation of Reverse Loop Sequences in tRNA3 Lys Genomic The Role of Nucleocapsid and U5 Stem/A-Rich (2013) (0)
CRISPR / Cas 9-Derived Mu tations Both Inhibit HIV-1 Replication and Accelerate Viral Escape Graphical (2016) (0)
The Use of Genotypic Assays for Monitoring the Development of Resistance to Antiviral Therapy for HIV-1 Infection and Other Chronic Viral Diseases (2009) (0)
Welcome from the conference chairman (2001) (0)
Packaging of Spliced Viral RNA Immunodeficiency Virus Type 1 on within the p 2 Region of Human Effects of a Single Amino Acid Substitution (2003) (0)
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA (2015) (0)
[Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection]. (1995) (0)
Introduction (1996) (0)
Roles of the K 101 E Substitution in HIV-1 Reverse Transcriptase in Resistance to 1 Rilpivirine and other Non-Nucleoside Reverse Transcriptase Inhibitors 2 3 (2013) (0)
immunodeficiency virus type 1 The effect of cyclosporine A on infection of susceptible cells by human (2008) (0)
Cell-to-cell transmission of HIV-1 between CD4+T-cells involves clathrin-mediated endocytosis (2011) (0)
O114 NNRTI mutations are efficiently transmitted within clusters of new HIV infections (2008) (0)
Chiamydia trachomaatis infections in infants (2005) (0)
Involvement of Macrophage-like Cellsin Growthof TumorsInducedby AvianSarcomaVirus1 (1983) (0)
Chapter 12 – Development and transmission of HIV drug resistance (2012) (0)
Comparative biochemical analysis of wildtype and drug resistant HIV-1 integrase subtypes B and C (2009) (0)
cells by NF-kappa B/Rel transcription factors. myeloid type 1 and cytokine gene expression in Regulation of human immunodeficiency virus (2014) (0)
Viral abrogation oflymphocyte mitogenesis: induction ofasoluble factor inhibitory tocellular proliferation (1980) (0)
Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis (2015) (0)
[Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds]. (1995) (0)
Effect of phorbol myristate acetate on cultured tumor cells derived from different stages of avian sarcoma virus (ASV)-induced neoplastic growth. (1987) (0)
The Effect of HIV-1 Integrase Resistance Mutations when Introduced into 1 (2014) (0)
[Differential expression of relevant Rous sarcoma tumor antigens in cultured cells]. (1977) (0)
HIV and Zika: When will we be able to end these epidemics? (2016) (0)
Viral mechanisms of immunosuppression : proceedings of a workshop (1985) (0)
Faculty Opinions recommendation of The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. (2009) (0)
At the forefront of retrovirology research: Frontiers of Retrovirology (2010) (0)
Induction of ReIA ( p 65 ) and IicBo Subunit Expression during Differentiation of Human Peripheral Blood Monocytes to Macrophages 1 (2005) (0)
, M multiplication . type 1 gene expression and virus activation of human immunodeficiency virus block Tat-tumor necrosis factor synergistic Transdominant mutants of I kappa B alpha (1996) (0)
Reviewer acknowledgement 2013 (2014) (0)
Staying ahead of viruses: a never ending task (2012) (0)
172 Monitoring HIV Drug Resistance as a Guide to Understanding Viral Pathogenesis (2011) (0)
Antiretroviral treatment-its progress and challenges (2003) (0)
Validation of molecular indicators of resistance transmission (MIRTs) for epidemiological studies of drug resistance transmission in HIV (2004) (0)
Superinfection and Recombination Can Rescue Replication-Deficient Multiply Drug-Resistant Variants of HIV-1 (2008) (0)
[Antiviral strategies in the replication of human immunodeficiency virus]. (1992) (0)
Subtype-Speciﬁc Analysis of the K65R Substitution in HIV-1 That Confers Hypersusceptibility to a Novel Nucleotide-Competing Reverse Transcriptase Inhibitor (2015) (0)
HIV-1 Entry Inhibitor Resistance (2014) (0)
The 16th International Conference on AIDS: will it leave a legacy? (2007) (0)
Antiretroviral therapy with integrase inhibitors: more options. (2013) (0)
Jean-Luc Darlix: Renaissance scientist and retrovirologist par excellence (2011) (0)
Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines (2014) (0)
Is Drug Resistance in First-Line Therapy against All Antiretroviral Agents Inevitable? (2015) (0)
CRISPR/Cas9: a double-edged sword when used to combat HIV infection (2016) (0)
Corrections - Investigation of the Active Center of Trypsin Using Photochromic Substrates. (1971) (0)
The Structure and Biology of HIV-1: (2021) (0)
HEW ANTI-VIRALS (1994) (0)
Reviewer acknowledgement 2014 (2015) (0)
Multidrug-Resistant Recombinant Viruses Which Can Lead to the Emergence of Superinfection in a Tat-Dependent Manner, Latent HIV-1 Can Be Reactivated by Cellular (2014) (0)
Molecular characterization of the development of the K65R and M184V drug resistance mutations in Subtype C HIV-1s (2007) (0)
Say no to boycott of AIDS conference (1999) (0)
What to do in therapy in the face of HIV drug resistance (2007) (0)
Dynamin-Dependent Endocytosis Cell-to-Cell Transmission via Productive Entry of HIV-1 during (2014) (0)
Jewish Religious Ethics Mandate Access to Antiretroviral Drugs in Developing Countries (2004) (0)
AIDS: Where Are We Now? (2004) (0)
Combination therapy for HIV infection : new perspectives : satellite symposium to the 19th International Congress on Chemotherapy, 18 July 1995, Montreal, Canada (1996) (0)
Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain (2017) (0)
Iconographies supplémentaires de l'article : Early HIV treatment to forestall drug resistance (2016) (0)
Reply to Heise and Philpott: The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics (2008) (0)
Contents (2012) (0)
Clade-Specific Tat Proteins Virus Type 1 Gene Expression by Regulation of Human Immunodeficiency (2005) (0)
Characterization of GPI2A, a Potent Inhibitor of HIV-1 Gene Expression and Viral Replication (1997) (0)
How will the ebola crisis impact the HIV epidemic? (2014) (0)
Identification of Mutations that Encode Drug Resistance in the Polymerase Gene of the Human Immunodeficiency Virus (1994) (0)
Reviewer acknowledgement 2015 (2016) (0)
Controversies in 21st century virology (2006) (0)
Faculty Opinions recommendation of Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. (2013) (0)
Design, Anti-Hiv Activity, Cellular Pharmacology and Conformation of BCH-189 [(±)3TC], A Novel Nucleoside Analogue (1992) (0)
Pre-exposure prophylaxis against HIV: pros and cons (2012) (0)
Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses (2016) (0)
Susceptibility of EBV-carrying B cell lines to infection by HIV-1: variability of production of progeny virus and expression of viral antigens. (1989) (0)
Use of new resistance markers to predict virologic response to antiretrovirals (2010) (0)
Introducing Future HIV Therapy (2007) (0)
to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation 2 (2013) (0)
' s response to reviews Title : Novel therapeutic strategies targeting HIV integrase (2012) (0)
Faculty Opinions recommendation of Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. (2012) (0)
Survey NF-kB activation and HIV-1 induced apoptosis (1999) (0)
HIV Vaccine Triage: Halakhic Considerations (2013) (0)
Altered pp60src kinase activity in regressing tumors induced by Rous sarcoma virus. (1987) (0)
Genotypic Assays for Monitoring Drug Resistance in HIV-1 Infection and for Other Chronic Viral Diseases (2017) (0)
[Importance of pharmacogenetics in antiretroviral metabolism and drug-transporters]. (2011) (0)
Inactivation ofHumanImmunodeficiency VirusType1inTissue Culture Fluid andinGenital Secretions bytheSpermicide Benzalkonium Chloride (1990) (0)
eJIAS: The Journal of HIV/AIDS Science and Medicine in the Developing World (2004) (0)
Four new lignans from the leaves and stems of Schisandra propinqua var. sinensis (2013) (0)
New findings on blockage of HIV-1 RNase H activity. (2009) (0)
HIV Drug Therapy in the Americas 8-10 May 2014, Rio de Janeiro, Brazil. (2014) (0)
Synthesis, Lipophilicity and Anti-HIV Activity of a New Brominated Analogue of Zidovudine. (2010) (0)
ReplicationInitiation Site Can Restore Viral That Are Distal from Deletion Mutations in the Immunodeficiency Virus Type 1 Gag Region Compensatory Point Mutations in the Human (2014) (0)
Advances in HIV Treatment Discussed (2014) (0)
HIV drug resistance against strand transfer integrase inhibitors (2017) (0)
Has the world ceased to care about HIV? And what can we do about it? (2015) (0)
CSCI Young Investigators Forum Abstracts (2009) (0)
Is there any hope for AIDS? (2004) (0)

This paper list is powered by the following services:

Other Resources About Mark Wainberg

en.wikipedia.org

What Schools Are Affiliated With Mark Wainberg?

Mark Wainberg is affiliated with the following schools:

Mark Wainberg's Academic­Influence.com Rankings